Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction
Ischemic heart disease remains one of the leading causes of death worldwide. Despite intensive research on the treatment of acute myocardial infarction, no effective therapy has shown clinical success. Therefore, novel therapeutic strategies are required to protect the heart from reperfusion injury....
Published in: | Frontiers in Cardiovascular Medicine |
---|---|
Main Authors: | , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doi.org/10.3389/fcvm.2021.687501 https://doaj.org/article/842ce44221234e128d2b9a13ac23d23d |
id |
ftdoajarticles:oai:doaj.org/article:842ce44221234e128d2b9a13ac23d23d |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:842ce44221234e128d2b9a13ac23d23d 2023-05-15T18:42:13+02:00 Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction Lucas Givre Claire Crola Da Silva Jon E. Swenson Jon M. Arnemo Guillemette Gauquelin-Koch Fabrice Bertile Etienne Lefai Ludovic Gomez 2021-07-01T00:00:00Z https://doi.org/10.3389/fcvm.2021.687501 https://doaj.org/article/842ce44221234e128d2b9a13ac23d23d EN eng Frontiers Media S.A. https://www.frontiersin.org/articles/10.3389/fcvm.2021.687501/full https://doaj.org/toc/2297-055X 2297-055X doi:10.3389/fcvm.2021.687501 https://doaj.org/article/842ce44221234e128d2b9a13ac23d23d Frontiers in Cardiovascular Medicine, Vol 8 (2021) cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy Diseases of the circulatory (Cardiovascular) system RC666-701 article 2021 ftdoajarticles https://doi.org/10.3389/fcvm.2021.687501 2022-12-31T06:24:04Z Ischemic heart disease remains one of the leading causes of death worldwide. Despite intensive research on the treatment of acute myocardial infarction, no effective therapy has shown clinical success. Therefore, novel therapeutic strategies are required to protect the heart from reperfusion injury. Interestingly, despite physical inactivity during hibernation, brown bears (Ursus arctos) cope with cardiovascular physiological conditions that would be detrimental to humans. We hypothesized that bear serum might contain circulating factors that could provide protection against cell injury. In this study, we sought to determine whether addition of bear serum might improve cardiomyocyte survival following hypoxia–reoxygenation. Isolated mouse cardiomyocytes underwent 45 min of hypoxia followed by reoxygenation. At the onset of reoxygenation, cells received fetal bovine serum (FBS; positive control), summer (SBS) or winter bear serum (WBS), or adult serums of other species, as indicated. After 2 h of reoxygenation, propidium iodide staining was used to evaluate cell viability by flow cytometry. Whereas, 0.5% SBS tended to decrease reperfusion injury, 0.5% WBS significantly reduced cell death, averaging 74.04 ± 7.06% vs. 79.20 ± 6.53% in the FBS group. This cardioprotective effect was lost at 0.1%, became toxic above 5%, and was specific to the bear. Our results showed that bear serum exerts a therapeutic effect with an efficacy threshold, an optimal dose, and a toxic effect on cardiomyocyte viability after hypoxia–reoxygenation. Therefore, the bear serum may be a potential source for identifying new therapeutic molecules to fight against myocardial reperfusion injury and cell death in general. Article in Journal/Newspaper Ursus arctos Directory of Open Access Journals: DOAJ Articles Frontiers in Cardiovascular Medicine 8 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy Diseases of the circulatory (Cardiovascular) system RC666-701 |
spellingShingle |
cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy Diseases of the circulatory (Cardiovascular) system RC666-701 Lucas Givre Claire Crola Da Silva Jon E. Swenson Jon M. Arnemo Guillemette Gauquelin-Koch Fabrice Bertile Etienne Lefai Ludovic Gomez Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction |
topic_facet |
cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy Diseases of the circulatory (Cardiovascular) system RC666-701 |
description |
Ischemic heart disease remains one of the leading causes of death worldwide. Despite intensive research on the treatment of acute myocardial infarction, no effective therapy has shown clinical success. Therefore, novel therapeutic strategies are required to protect the heart from reperfusion injury. Interestingly, despite physical inactivity during hibernation, brown bears (Ursus arctos) cope with cardiovascular physiological conditions that would be detrimental to humans. We hypothesized that bear serum might contain circulating factors that could provide protection against cell injury. In this study, we sought to determine whether addition of bear serum might improve cardiomyocyte survival following hypoxia–reoxygenation. Isolated mouse cardiomyocytes underwent 45 min of hypoxia followed by reoxygenation. At the onset of reoxygenation, cells received fetal bovine serum (FBS; positive control), summer (SBS) or winter bear serum (WBS), or adult serums of other species, as indicated. After 2 h of reoxygenation, propidium iodide staining was used to evaluate cell viability by flow cytometry. Whereas, 0.5% SBS tended to decrease reperfusion injury, 0.5% WBS significantly reduced cell death, averaging 74.04 ± 7.06% vs. 79.20 ± 6.53% in the FBS group. This cardioprotective effect was lost at 0.1%, became toxic above 5%, and was specific to the bear. Our results showed that bear serum exerts a therapeutic effect with an efficacy threshold, an optimal dose, and a toxic effect on cardiomyocyte viability after hypoxia–reoxygenation. Therefore, the bear serum may be a potential source for identifying new therapeutic molecules to fight against myocardial reperfusion injury and cell death in general. |
format |
Article in Journal/Newspaper |
author |
Lucas Givre Claire Crola Da Silva Jon E. Swenson Jon M. Arnemo Guillemette Gauquelin-Koch Fabrice Bertile Etienne Lefai Ludovic Gomez |
author_facet |
Lucas Givre Claire Crola Da Silva Jon E. Swenson Jon M. Arnemo Guillemette Gauquelin-Koch Fabrice Bertile Etienne Lefai Ludovic Gomez |
author_sort |
Lucas Givre |
title |
Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction |
title_short |
Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction |
title_full |
Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction |
title_fullStr |
Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction |
title_full_unstemmed |
Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction |
title_sort |
cardiomyocyte protection by hibernating brown bear serum: toward the identification of new protective molecules against myocardial infarction |
publisher |
Frontiers Media S.A. |
publishDate |
2021 |
url |
https://doi.org/10.3389/fcvm.2021.687501 https://doaj.org/article/842ce44221234e128d2b9a13ac23d23d |
genre |
Ursus arctos |
genre_facet |
Ursus arctos |
op_source |
Frontiers in Cardiovascular Medicine, Vol 8 (2021) |
op_relation |
https://www.frontiersin.org/articles/10.3389/fcvm.2021.687501/full https://doaj.org/toc/2297-055X 2297-055X doi:10.3389/fcvm.2021.687501 https://doaj.org/article/842ce44221234e128d2b9a13ac23d23d |
op_doi |
https://doi.org/10.3389/fcvm.2021.687501 |
container_title |
Frontiers in Cardiovascular Medicine |
container_volume |
8 |
_version_ |
1766231836766240768 |